Prof. Jean-François Dufour

Prof. Jean-François Dufour studied mathematics at the University of Geneva, Switzerland, and received his medical degree from the Geneva Medical School. After training in internal medicine at the University Hospital Geneva and the University Hospital Bern, he joined the laboratory of Professor

Articles: 7

Videos & Slides: 7

59- PROF DUFOUR DISCUSSES BEST PRACTICES ABOUT THE DIAGNOSIS OF NASH

Cancers and NASH

Patients and physicians have to know that NASH increases the risk to develop cancers. Specific surveillance has to be implemented when indicated. Hepatocellular carcinoma is rare in patients with NASH without advanced fibrosis, but seems to occur not rarely when the liver is not yet cirrhotic. Some molecular mechanisms seem specific to NASH-related HCC. The management is similar to HCC with other underlying liver disease. Patients with NASH-related HCC may respond less to immuno-oncology.

November 18, 2022

Diagnosis Epidemiology

Cancers and NASH

Dr. Jean-François Dufour (Switzerland) reviews the association between cancers and NASH, where he highlights the causes of death in NAFLD patients, in which cardiovascular diseases and non-liver cancer with 38.3% and 18.7% are identified as some of the major causes.

March 10, 2022

Nash Treatment PPAR Agonists

PPARs: State-of-the-art by Prof. J.-F. Dufour

Prof. Jean-François Dufour (Switzerland) explores PPARs to NAFLD28 as a systemic disease with metabolic changes in Adipose tissue, skeletal muscle, liver and endothelium.

April 24, 2020

Comorbidities Management Nash Treatment

The role of comorbidities in NASH management: a holistic approach

Prof Jean-François Dufour, Switzerland, addresses the important problem of comorbidities in NASH management including diabetes, cardiovascular disease, cancer. This video was filmed in Boston during the Liver meeting 2019.